Overall, our study establishes the potential for clinical application of the CSF1R inhibitor JNJ-527 in Alzheimer’s disease and other neurodegenerative disorders where neuroinflammation may play a role. The gene discussed is CSF1R; the disease is early-onset autosomal dominant Alzheimer disease.